ENHERTU (fam-trastuzumab deruxtecan) represents a paradigmatic shift in oncological therapeutics, fundamentally altering treatment landscapes for HER2-positive cancers worldwide. This cutting-edge antibody-drug conjugate, born from collaborative innovation between Daiichi Sankyo and AstraZeneca, has achieved unprecedented regulatory success with approvals encompassing breast cancer, gastric...